Chimeric antigen receptor-T (CAR-T) cell therapy has been facing a challenging time with the recent the US Food And Drug Administration probe into the safety of certain types of CAR-Ts, which in the case of Swiss firm CRISPR Therapeutics AG have led it to review its development pipeline.
For CAR-T-focused Japanese biotech firm Noile-Immune Biotech, Inc., however, its hopes for the technology are still high